Logo image of AGL

AGILON HEALTH INC (AGL) Stock Fundamental Analysis

USA - NYSE:AGL - US00857U1079 - Common Stock

1.0396 USD
+0.02 (+1.92%)
Last: 10/10/2025, 9:41:06 AM
Fundamental Rating

3

AGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. The financial health of AGL is average, but there are quite some concerns on its profitability. AGL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGL had negative earnings in the past year.
In the past year AGL has reported a negative cash flow from operations.
In the past 5 years AGL always reported negative net income.
In the past 5 years AGL always reported negative operating cash flow.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

AGL has a Return On Assets of -18.43%. This is amonst the worse of the industry: AGL underperforms 82.18% of its industry peers.
AGL's Return On Equity of -77.19% is on the low side compared to the rest of the industry. AGL is outperformed by 76.24% of its industry peers.
Industry RankSector Rank
ROA -18.43%
ROE -77.19%
ROIC N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

AGL's Gross Margin of 0.50% is on the low side compared to the rest of the industry. AGL is outperformed by 81.19% of its industry peers.
In the last couple of years the Gross Margin of AGL has declined.
The Profit Margin and Operating Margin are not available for AGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

5

2. Health

2.1 Basic Checks

AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGL has been increased compared to 1 year ago.
AGL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AGL has been reduced compared to a year ago.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

AGL has an Altman-Z score of 1.69. This is a bad value and indicates that AGL is not financially healthy and even has some risk of bankruptcy.
AGL has a worse Altman-Z score (1.69) than 60.40% of its industry peers.
There is no outstanding debt for AGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.69
ROIC/WACCN/A
WACC9.43%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.16 indicates that AGL should not have too much problems paying its short term obligations.
AGL has a Current ratio of 1.16. This is in the lower half of the industry: AGL underperforms 64.36% of its industry peers.
AGL has a Quick Ratio of 1.16. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.16, AGL is doing worse than 60.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for AGL have decreased strongly by -35.09% in the last year.
The Revenue has grown by 15.30% in the past year. This is quite good.
AGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.14% yearly.
EPS 1Y (TTM)-35.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-257.14%
Revenue 1Y (TTM)15.3%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%-5.92%

3.2 Future

AGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.86% yearly.
AGL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.46% yearly.
EPS Next Y-2.19%
EPS Next 2Y17.5%
EPS Next 3Y17.04%
EPS Next 5Y19.86%
Revenue Next Year-3.84%
Revenue Next 2Y1.06%
Revenue Next 3Y4.68%
Revenue Next 5Y9.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as AGL's earnings are expected to grow with 17.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.5%
EPS Next 3Y17.04%

More info and screens

0

5. Dividend

5.1 Amount

AGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGILON HEALTH INC

NYSE:AGL (10/10/2025, 9:41:06 AM)

1.0396

+0.02 (+1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)10-30 2025-10-30/amc
Inst Owners69.32%
Inst Owner Change0%
Ins Owners1.92%
Ins Owner Change3.38%
Market Cap430.83M
Analysts55.38
Price Target1.99 (91.42%)
Short Float %7.45%
Short Ratio1.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)153.92%
Min EPS beat(2)-114.66%
Max EPS beat(2)422.51%
EPS beat(4)1
Avg EPS beat(4)31.03%
Min EPS beat(4)-171.08%
Max EPS beat(4)422.51%
EPS beat(8)3
Avg EPS beat(8)10.35%
EPS beat(12)4
Avg EPS beat(12)0.71%
EPS beat(16)5
Avg EPS beat(16)-17.79%
Revenue beat(2)1
Avg Revenue beat(2)-2.61%
Min Revenue beat(2)-6.13%
Max Revenue beat(2)0.91%
Revenue beat(4)1
Avg Revenue beat(4)-2.02%
Min Revenue beat(4)-6.13%
Max Revenue beat(4)0.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.79%
Revenue beat(12)7
Avg Revenue beat(12)0.7%
Revenue beat(16)11
Avg Revenue beat(16)0.84%
PT rev (1m)-1.64%
PT rev (3m)-53.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45.91%
EPS NY rev (1m)0.81%
EPS NY rev (3m)-85.48%
Revenue NQ rev (1m)-0.41%
Revenue NQ rev (3m)-2.57%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-2.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.35
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS14.24
BVpS0.99
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.43%
ROE -77.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 0.5%
FCFM N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
F-Score4
Asset Turnover3.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.46%
Cap/Sales 0.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z 1.69
F-Score4
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)186.26%
Cap/Depr(5y)133.4%
Cap/Sales(3y)0.87%
Cap/Sales(5y)0.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-257.14%
EPS Next Y-2.19%
EPS Next 2Y17.5%
EPS Next 3Y17.04%
EPS Next 5Y19.86%
Revenue 1Y (TTM)15.3%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%-5.92%
Revenue Next Year-3.84%
Revenue Next 2Y1.06%
Revenue Next 3Y4.68%
Revenue Next 5Y9.46%
EBIT growth 1Y-45.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.24%
EBIT Next 3Y24.83%
EBIT Next 5Y18.95%
FCF growth 1Y38.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.88%
OCF growth 3YN/A
OCF growth 5YN/A